The Journey of Tofacitinib

Tofacitinib is rapidly and well absorbed from the GI tract with
absolute oral bioavailability of approximately 74%. Peak plasma concentrations are achieved within
0.5-1 hour — one of the fastest oral drug absorption profiles, consistent with its small molecular
size (MW ~312 Da) and lipophilic-hydrophilic balance enabling rapid membrane permeation. The drug
is available as immediate-release 5 mg and 10 mg tablets and as an extended-release 11 mg tablet
(equivalent to 10 mg IR twice daily). A high-fat meal does not significantly affect total bioavailability
but modestly reduces Cmax. The IR formulation is dosed twice daily (5 mg BID for RA, 10 mg BID
induction for UC). Extended-release 11 mg QD (Xeljanz XR) offers once-daily convenience for RA
maintenance. No prodrug activation is required — tofacitinib is directly pharmacologically active
upon absorption.

Tofacitinib distributes moderately into tissues with a volume of
distribution of approximately 87 L. Plasma protein binding is approximately 40%, lower than most
small-molecule drugs, predominantly to albumin. The low protein binding means a higher free fraction
is available for cellular uptake — tofacitinib enters cells readily to reach its intracellular
target (JAKs are cytoplasmic kinases). The drug penetrates well into inflamed joints and synovial
tissue. CNS penetration occurs, though neurological adverse effects are uncommon. Red blood cell
partitioning is approximately 60:40 (plasma:RBC), lower than calcineurin inhibitors. Tofacitinib
distributes to the gut mucosa in concentrations supporting its local immunosuppressive effect in
ulcerative colitis. No specific tissue accumulation is known.

Janus kinases (JAK1, JAK2, JAK3, TYK2) are non-receptor tyrosine
kinases constitutively associated with cytokine receptor cytoplasmic domains. Upon cytokine binding,
receptor dimerization brings two JAKs into proximity, enabling trans-phosphorylation and activation.
Activated JAKs phosphorylate tyrosine residues on the receptor cytoplasmic tail, creating docking
sites for STAT (signal transducer and activator of transcription) proteins. STATs are phosphorylated
by JAKs, dimerize, and translocate to the nucleus to activate cytokine-responsive genes.
Tofacitinib binds the ATP-binding pocket of JAK1 and JAK3 (and to a lesser extent JAK2 and TYK2)
with IC50 values of ~3.2 nM (JAK1) and ~1.6 nM (JAK3), blocking cytokine signaling from receptors
using JAK1/JAK3 heterodimers (common gamma chain-associated receptors: IL-2R, IL-4R, IL-7R, IL-9R,
IL-15R, IL-21R) and JAK1/JAK2 (IFN signaling). This simultaneously interrupts multiple pro-
inflammatory cytokine axes driving rheumatoid arthritis and UC inflammation.

Tofacitinib is metabolized primarily by CYP3A4 (approximately 70%)
and CYP2C19 (approximately 30%) via oxidation and methylation. The major metabolite is an N-oxide
product via CYP3A4-mediated oxidation — pharmacologically inactive and not a clinically relevant
contributor to efficacy or toxicity. Approximately 30% of tofacitinib AUC is contributed by
metabolites collectively. Potent CYP3A4 inhibitors (ketoconazole) increase tofacitinib AUC
approximately 2-fold; moderate CYP3A4 inhibitors plus strong CYP2C19 inhibitors (fluconazole)
increase AUC approximately 3-fold — the latter combination requiring dose reduction. Strong CYP3A4
inducers (rifampicin) reduce AUC by approximately 84% and are contraindicated or require dose
adjustment. Tofacitinib does not significantly inhibit any major CYP enzyme at therapeutic
concentrations.

Tofacitinib is eliminated via both renal (~30%) and hepatic (~70%)
routes. Approximately 22% of the dose is excreted unchanged in urine, with the remainder as
metabolites. Elimination half-life of tofacitinib is approximately 3 hours for the immediate-release
formulation (explaining the twice-daily dosing requirement) and approximately 6 hours for the
extended-release formulation. Despite the short half-life, pharmacodynamic suppression of JAK-
STAT signaling outlasts plasma half-life by several hours. Severe renal impairment increases
tofacitinib AUC by approximately 40%, requiring dose reduction. Moderate hepatic impairment
increases AUC by approximately 65%, also requiring dose reduction. Tofacitinib is not removed
efficiently by hemodialysis. Dose adjustments are provided for renal (CrCl <60 mL/min) and hepatic
(Child-Pugh B) impairment.

Tofacitinib is approved for rheumatoid arthritis (inadequate
response to methotrexate), psoriatic arthritis, ulcerative colitis (including as an induction agent),
and polyarticular juvenile idiopathic arthritis. In RA, ORAL trials demonstrated efficacy comparable
to adalimumab. Post-marketing safety surveillance (ORAL Surveillance) revealed higher rates of
major adverse cardiovascular events (MACE) and thromboembolic events (VTE, PE) and malignancy with
10 mg BID vs. TNF inhibitors in patients with CV risk factors — leading to a boxed warning and
FDA label updates restricting use to patients who have failed TNF inhibitors. Serious infections
(including reactivation of herpes zoster and tuberculosis) and malignancy risk are class effects
shared with biological immunosuppressants. Unlike biologics, tofacitinib requires no injection
and has rapid onset (clinically meaningful improvement within 2 weeks).